Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples. It provides analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry. The Production Enhancement segment includes products and services relating to reservoir well completions, perforations, stimulations and production. It provides integrated diagnostic services to evaluate the effectiveness of well completions. The Reservoir Management segment combines and integrates information from reservoir description and production enhancement services to increase production and recovery of oil and gas from its clients' reservoirs.
Industry, Sector and Symbol:
- Sector: Oils/Energy
- Industry: Oil Related Services and Equipment
- Sub-Industry: N/A
- Symbol: NYSE:CLB
- CUSIP: N/A
- Web: www.corelab.com
Capitalization:- Market Cap: $4.30391 billion
- Outstanding Shares: 44,138,000
Average Prices:- 50 Day Moving Avg: $92.99
- 200 Day Moving Avg: $103.90
- 52 Week Range: $86.55 - $125.83
P/E:- Trailing P/E Ratio: 60.53
- Foreward P/E Ratio: 37.65
- P/E Growth: 1.22
Sales & Book Value:- Annual Revenue: $614.73 million
- Price / Sales: 7.00
- Book Value: $3.34 per share
- Price / Book: 29.19
Dividend:- Annual Dividend: $2.20
- Dividend Yield: 2.3%
Profitability:- EBIDTA: $123.03 million
- Net Margins: 11.80%
- Return on Equity: 49.29%
- Return on Assets: 13.35%
Debt:- Debt-to-Equity Ratio: 1.54%
- Current Ratio: 2.05%
- Quick Ratio: 1.69%
Misc:- Average Volume: 753,770 shs.
- Beta: 1.6
- Short Ratio: 14.53
Frequently Asked Questions for Core Laboratories N.V. (NYSE:CLB)
What is Core Laboratories N.V.'s stock symbol?
Core Laboratories N.V. trades on the New York Stock Exchange (NYSE) under the ticker symbol "CLB."
How often does Core Laboratories N.V. pay dividends? What is the dividend yield for Core Laboratories N.V.?
Core Laboratories N.V. announced a quarterly dividend on Thursday, July 6th. Investors of record on Monday, July 17th will be given a dividend of $0.55 per share on Monday, August 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.26%. The ex-dividend date is Thursday, July 13th. View Core Laboratories N.V.'s Dividend History.
How were Core Laboratories N.V.'s earnings last quarter?
Core Laboratories N.V. (NYSE:CLB) issued its quarterly earnings data on Monday, July, 24th. The company reported $0.52 EPS for the quarter, beating the Zacks' consensus estimate of $0.51 by $0.01. The firm earned $163.90 million during the quarter, compared to analyst estimates of $168.23 million. Core Laboratories N.V. had a return on equity of 49.29% and a net margin of 11.80%. Core Laboratories N.V.'s quarterly revenue was up 10.7% compared to the same quarter last year. During the same period last year, the business earned $0.35 EPS. View Core Laboratories N.V.'s Earnings History.
When will Core Laboratories N.V. make its next earnings announcement?
What guidance has Core Laboratories N.V. issued on next quarter's earnings?
Core Laboratories N.V. issued an update on its third quarter earnings guidance on Tuesday, September, 5th. The company provided earnings per share guidance of ~$0.44 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.56. The company issued revenue guidance of ~$161 million, compared to the consensus revenue estimate of $168.53 million.
Where is Core Laboratories N.V.'s stock going? Where will Core Laboratories N.V.'s stock price be in 2017?
13 brokerages have issued 1-year target prices for Core Laboratories N.V.'s stock. Their predictions range from $91.00 to $136.00. On average, they anticipate Core Laboratories N.V.'s stock price to reach $113.70 in the next year. View Analyst Ratings for Core Laboratories N.V..
Who are some of Core Laboratories N.V.'s key competitors?
Some companies that are related to Core Laboratories N.V. include RPC (RES), Antero Midstream GP LP (AMGP), Oceaneering International (OII), John Wood Group PLC (WG), McDermott International (MDR), Frank's International N.V. (FI), Superior Energy Services (SPN), Petrofac Limited (PFC), Forum Energy Technologies (FET), Tidewater (TDW), Helix Energy Solutions Group (HLX), Exterran Corporation (EXTN), NCS Multistage Holdings (NCSM), Archrock Partners, L.P. (APLP), USA Compression Partners, LP (USAC), Fairmount Santrol Holdings (FMSA), Archrock (AROC) and Newpark Resources (NR).
Who are Core Laboratories N.V.'s key executives?
Core Laboratories N.V.'s management team includes the folowing people:
- David M. Demshur, Chairman of the Supervisory Board, President, Chief Executive Officer
- Richard L. Bergmark, Chief Financial Officer, Executive Vice President, Member of the Supervisory Board
- Monty L. Davis, Chief Operating Officer, Senior Vice President
- Christopher S. Hill, Vice President, Chief Accounting Officer
- Mark F. Elvig, Vice President, Secretary, General Counsel
- Gwendolyn Y. Schreffler, Vice President, Corporate Development & Investor Relations
- Martha Z. Carnes, Member of the Supervisory Board
- Charles L. Dunlap, Member of the Supervisory Board
- Jan Willem Sodderland, Member of the Supervisory Board
- Michael Straughen, Member of the Supervisory Board
Who owns Core Laboratories N.V. stock?
Core Laboratories N.V.'s stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include
WCM INVESTMENT MANAGEMENT
(10.17%), WCM Investment Management CA (10.04%), Vanguard Group Inc. (8.32%), Sustainable Growth Advisers LP (5.31%), Earnest Partners LLC (4.16%) and Kayne Anderson Rudnick Investment Management LLC (3.86%). Company insiders that own Core Laboratories N.V. stock include Jan Willem Sodderland, Martha Z Carnes and Michael Straughen. View Institutional Ownership Trends for Core Laboratories N.V..
Who sold Core Laboratories N.V. stock? Who is selling Core Laboratories N.V. stock?
Core Laboratories N.V.'s stock was sold by a variety of institutional investors in the last quarter, including Royal Bank of Canada, RiverPark Advisors LLC, American Century Companies Inc., Macquarie Group Ltd., Jackson Square Partners LLC, Bank of Montreal Can, Wells Fargo & Company MN and Capital World Investors. View Insider Buying and Selling for Core Laboratories N.V..
Who bought Core Laboratories N.V. stock? Who is buying Core Laboratories N.V. stock?
Core Laboratories N.V.'s stock was purchased by a variety of institutional investors in the last quarter, including Sustainable Growth Advisers LP, WCM Investment Management CA, Neuberger Berman Group LLC, Sei Investments Co., JPMorgan Chase & Co., Forsta AP Fonden, Vanguard Group Inc. and Northern Trust Corp. Company insiders that have bought Core Laboratories N.V. stock in the last two years include Jan Willem Sodderland, Martha Z Carnes and Michael Straughen. View Insider Buying and Selling for Core Laboratories N.V..
How do I buy Core Laboratories N.V. stock?
Shares of Core Laboratories N.V. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Core Laboratories N.V.'s stock price today?
One share of Core Laboratories N.V. stock can currently be purchased for approximately $97.51.
MarketBeat Community Rating for Core Laboratories N.V. (NYSE CLB)MarketBeat's community ratings are surveys of what our community members think about Core Laboratories N.V. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Core Laboratories N.V. (NYSE:CLB) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 7 Hold Ratings, 5 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.31) |
| Consensus Price Target: | $113.70 (16.60% upside) |
Analysts' Ratings History for Core Laboratories N.V. (NYSE:CLB)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/7/2017 | Royal Bank Of Canada | Lower Price Target | Outperform -> Outperform | $115.00 -> $112.00 | Low |  |
| 9/1/2017 | Cowen and Company | Reiterated Rating | Hold | $100.00 | Medium | |
| 8/24/2017 | Credit Suisse Group | Upgrade | Neutral -> Outperform | $110.00 | Medium | |
| 8/7/2017 | Morgan Stanley | Lower Price Target | Overweight -> Overweight | $130.00 -> $125.00 | Medium | |
| 7/26/2017 | Citigroup Inc. | Lower Price Target | Neutral | $102.00 -> $100.00 | Low | |
| 7/26/2017 | Piper Jaffray Companies | Set Price Target | Hold | $97.00 | Medium | |
| 4/22/2017 | Scotiabank | Set Price Target | Hold | $136.00 | Low | |
| 4/21/2017 | ABN Amro | Upgrade | Hold | | Low | |
| 4/21/2017 | Loop Capital | Upgrade | Hold -> Buy | $125.00 -> $130.00 | Low | |
| 3/23/2017 | Tudor Pickering | Initiated Coverage | Hold | | Low | |
| 12/7/2016 | Stephens | Downgrade | Equal Weight -> Sell | $91.00 | N/A | |
| 12/6/2016 | Guggenheim | Downgrade | Buy -> Neutral | | N/A | |
| 10/5/2016 | DA Davidson | Initiated Coverage | Buy | $136.00 | N/A | |
| 7/12/2016 | J P Morgan Chase & Co | Downgrade | Neutral -> Underweight | | N/A | |
| 6/13/2016 | KLR Group | Reiterated Rating | Buy | $166.00 -> $180.00 | N/A | |
| 4/23/2016 | Simmons | Reiterated Rating | Hold | $105.00 -> $115.00 | N/A | |
| 3/28/2016 | Howard Weil | Boost Price Target | | $112.00 | N/A | |
| 2/10/2016 | ING Group | Lower Price Target | Hold | $125.00 -> $112.00 | N/A | |
| 2/2/2016 | William Blair | Reiterated Rating | Outperform | | N/A | |
| 1/29/2016 | SunTrust Banks, Inc. | Lower Price Target | Buy | $123.00 -> $109.00 | N/A | |
| 1/29/2016 | Iberia Capital | Lower Price Target | Outperform | $140.00 -> $115.00 | N/A | |
| 1/26/2016 | HSBC Holdings plc | Downgrade | Hold -> Reduce | | N/A | |
| 1/11/2016 | Oppenheimer Holdings, Inc. | Initiated Coverage | Market Perform | | N/A | |
| 9/30/2015 | Sterne Agee CRT | Lower Price Target | Neutral | $113.00 -> $108.00 | N/A | |
(Data available from 9/25/2015 forward)
Earnings History for Core Laboratories N.V. (NYSE:CLB)Earnings History by Quarter for Core Laboratories N.V. (NYSE CLB)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/23/2017 | | $0.61 | | | | | N/A | |
| 7/24/2017 | 6/30/2017 | $0.51 | $0.52 | $168.23 million | $163.90 million | View | N/A | |
| 4/19/2017 | 3/31/2017 | $0.39 | $0.42 | $150.44 million | $157.81 million | View | N/A | |
| 1/25/2017 | 12/31/2016 | $0.41 | $0.41 | $145.78 million | $149.54 million | View | N/A | |
| 10/19/2016 | Q316 | $0.38 | $0.38 | $155.72 million | $143.50 million | View | N/A | |
| 7/20/2016 | Q216 | $0.35 | $0.35 | $146.37 million | $148.10 million | View | N/A | |
| 4/20/2016 | Q116 | $0.37 | $0.37 | $161.24 million | $153.65 million | View | N/A | |
| 1/27/2016 | Q415 | $0.65 | $0.65 | $179.48 million | $182.70 million | View | Listen | |
| 10/21/2015 | Q315 | $0.83 | $0.83 | $203.29 million | $197.27 million | View | Listen | |
| 7/22/2015 | Q215 | $0.77 | $0.82 | $195.13 million | $204.00 million | View | Listen | |
| 4/22/2015 | Q115 | $0.85 | $0.86 | $211.82 million | $213.64 million | View | N/A | |
| 1/28/2015 | Q414 | $1.54 | $1.54 | $280.18 million | $278.60 million | View | N/A | |
| 10/22/2014 | Q314 | $1.52 | $1.53 | $284.30 million | $276.14 million | View | Listen | |
| 7/23/2014 | Q214 | $1.35 | $1.35 | $269.70 million | $267.56 million | View | Listen | |
| 4/23/2014 | Q114 | $1.45 | $1.45 | $283.02 million | $262.90 million | View | Listen | |
| 1/30/2014 | Q413 | $1.40 | $1.43 | $278.55 million | $276.30 million | View | Listen | |
| 10/17/2013 | Q313 | $1.34 | $1.36 | $267.21 million | $273.16 million | View | N/A | |
| 7/17/2013 | Q2 2013 | $1.31 | $1.32 | $267.24 million | $263.14 million | View | Listen | |
| 4/17/2013 | Q1 2013 | $1.15 | $1.22 | $260.90 million | $260.90 million | View | Listen | |
| 1/30/2013 | Q4 2012 | $1.13 | $1.17 | $246.49 million | $254.46 million | View | Listen | |
| 10/17/2012 | | $1.10 | $1.13 | | | View | N/A | |
| 7/18/2012 | | $1.16 | $1.16 | | | View | N/A | |
| 4/18/2012 | | $1.07 | $1.06 | | | View | N/A | |
| 2/1/2012 | | $1.08 | $1.09 | | | View | N/A | |
| 10/19/2011 | | $0.99 | $0.93 | | | View | N/A | |
| 4/19/2011 | | $0.75 | $0.77 | | | View | N/A | |
| 2/9/2011 | | $0.81 | $0.84 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Core Laboratories N.V. (NYSE:CLB)2017 EPS Consensus Estimate: $2.62
2018 EPS Consensus Estimate: $3.44
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $0.39 | $0.81 | $0.53 |
| Q2 2017 | 3 | $0.47 | $0.88 | $0.61 |
| Q3 2017 | 3 | $0.55 | $0.97 | $0.72 |
| Q4 2017 | 3 | $0.54 | $1.03 | $0.76 |
| Q1 2018 | 1 | $0.73 | $0.73 | $0.73 |
| Q2 2018 | 1 | $0.84 | $0.84 | $0.84 |
| Q3 2018 | 1 | $1.00 | $1.00 | $1.00 |
| Q4 2018 | 2 | $0.65 | $1.08 | $0.87 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Core Laboratories N.V. (NYSE:CLB)| Most Recent Dividend: | 8/14/2017 |
| Annual Dividend: | $2.20 |
| Dividend Yield: | 2.26% |
| Dividend Growth: | 19.80% (3 Year Average) |
| Payout Ratio: | 134.15% (Trailing 12 Months of Earnings)
110.00% (Based on This Year's Estimates)
84.94% (Based on Next Year's Estimates)
|
Dividend History by Quarter for Core Laboratories N.V. (NYSE CLB)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 7/6/2017 | Quarterly | $0.55 | 2.11% | 7/13/2017 | 7/17/2017 | 8/14/2017 |
| 4/19/2017 | quarterly | $0.55 | 1.98% | 4/27/2017 | 4/28/2017 | 5/23/2017 |
| 1/10/2017 | Quarterly | $0.55 | 1.8% | 1/18/2017 | 1/20/2017 | 2/17/2017 |
| 10/11/2016 | Quarterly | $0.55 | 1.95% | 10/19/2016 | 10/21/2016 | 11/22/2016 |
| 7/7/2016 | Quarterly | $0.55 | | 7/14/2016 | 7/18/2016 | 8/15/2016 |
| 4/15/2016 | Quarterly | $0.55 | | 5/2/2016 | 5/4/2016 | 5/24/2016 |
| 1/11/2016 | Quarterly | $0.55 | 2.28% | 1/20/2016 | 1/22/2016 | 2/19/2016 |
| 10/13/2015 | Quarterly | $0.55 | | 10/21/2015 | 10/23/2015 | 11/24/2015 |
| 7/7/2015 | quarterly | $0.55 | 2.02% | 7/15/2015 | 7/17/2015 | 8/17/2015 |
| 1/12/2015 | | $0.55 | | 1/21/2015 | 1/23/2015 | 2/20/2015 |
| 10/6/2014 | quarterly | $0.50 | 1.39% | 10/16/2014 | 10/17/2014 | 11/25/2014 |
| 7/8/2014 | quarterly | $0.50 | | 7/16/2014 | 7/18/2014 | 8/18/2014 |
| 4/14/2014 | quarterly | $0.50 | 1.33% | 4/23/2014 | 4/25/2014 | 5/23/2014 |
| 1/13/2014 | quarterly | $0.50 | 1.05% | 1/22/2014 | 1/24/2014 | 2/21/2014 |
| 10/8/2013 | quarterly | $0.32 | 0.73% | 10/16/2013 | 10/18/2013 | 11/20/2013 |
| 7/9/2013 | quarterly | $0.32 | 0.82% | 7/17/2013 | 7/19/2013 | 8/19/2013 |
| 4/15/2013 | quarterly | $0.32 | 1.01% | 4/24/2013 | 4/26/2013 | 5/24/2013 |
| 1/11/2013 | quarterly | $0.32 | | | 1/22/2013 | 2/22/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Core Laboratories N.V. (NYSE:CLB)Insider Ownership Percentage: 1.00%
Insider Trades by Quarter for Core Laboratories N.V. (NYSE:CLB)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 2/1/2017 | Michael Straughen | Director | Buy | 106 | $118.65 | $12,576.90 | |
| 1/30/2017 | Martha Z Carnes | Director | Buy | 200 | $115.20 | $23,040.00 | |
| 2/2/2016 | Jan Willem Sodderland | Director | Buy | 300 | $93.90 | $28,170.00 | |
| 5/12/2015 | Michael C Kearney | Director | Sell | 1,000 | $128.52 | $128,520.00 | |
| 11/17/2014 | Mark F Elvig | VP | Sell | 1,000 | $138.03 | $138,030.00 | |
| 7/28/2014 | Richard L Bergmark | CFO | Buy | 7,000 | $147.31 | $1,031,170.00 | |
| 3/7/2014 | Michael Kearney | Director | Sell | 2,000 | $193.00 | $386,000.00 | |
| 2/14/2014 | Mark Elvig | VP | Sell | 1,500 | $186.64 | $279,960.00 | |
| 10/21/2013 | Monty L Davis | COO | Sell | 5,704 | $197.33 | $1,125,570.32 | |
| 8/7/2013 | Richard Bergmark | CFO | Sell | 20,000 | $149.58 | $2,991,600.00 | |
| 7/25/2013 | Charles Brigham Miller | CAO | Sell | 11,648 | $147.81 | $1,721,690.88 | |
| 7/25/2013 | Monty L Davis | COO | Sell | 5,948 | $149.12 | $886,965.76 | |
(Data available from 1/1/2013 forward)
Headline Trends for Core Laboratories N.V. (NYSE:CLB)
Latest Headlines for Core Laboratories N.V. (NYSE:CLB)
| Source: |
|
| Date | Headline |
|---|
 | Core Laboratories NV – Value Analysis (NYSE:CLB) : September 19, 2017
finance.yahoo.com - September 19 at 10:18 PM |
| Core Laboratories NV breached its 50 day moving average in a Bullish Manner : CLB-US : September 18, 2017
finance.yahoo.com - September 18 at 3:27 PM |
 | Core Laboratories N.V. (CLB) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - September 18 at 12:16 AM |
 | JPMorgan Has 5 Top Pick Oil Service Stocks for the Rest of 2017
247wallst.com - September 13 at 6:29 PM |
| Oil Companies on Slippery Ground as Harvey Hampers Production
finance.yahoo.com - September 12 at 5:53 PM |
| Core Laboratories N.V. (CLB) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - September 9 at 8:38 PM |
| Correlation between Crude Oil and Halliburton on September 5
finance.yahoo.com - September 8 at 5:35 PM |
| Core Laboratories N.V. (CLB) PT Lowered to $112.00 at Royal Bank Of Canada
www.americanbankingnews.com - September 7 at 1:00 PM |
| Core Laboratories N.V. (CLB) Updates Q3 Earnings Guidance
www.americanbankingnews.com - September 5 at 9:10 PM |
| Core Lab Reports On Impact Of Hurricane Harvey, Updates Third Quarter 2017 Guidance
finance.yahoo.com - September 5 at 6:47 PM |
| Cowen and Company Reaffirms Hold Rating for Core Laboratories N.V. (CLB)
www.americanbankingnews.com - September 4 at 9:26 PM |
| Core Laboratories N.V. (CLB) Lowered to Sell at ValuEngine
www.americanbankingnews.com - September 3 at 6:32 PM |
| Core Laboratories N.V. (CLB) Receives "Buy" Rating from Royal Bank Of Canada
www.americanbankingnews.com - September 2 at 6:20 AM |
 | First Week of October 20th Options Trading For Core Laboratories (CLB)
www.nasdaq.com - August 30 at 4:18 PM |
| ETFs with exposure to Core Laboratories NV : August 25, 2017
finance.yahoo.com - August 25 at 6:59 PM |
| Core Laboratories (CLB) Down 17.7% Since Earnings Report: Can It Rebound? - Nasdaq
www.nasdaq.com - August 25 at 3:24 AM |
| Core Laboratories Stock Getting Very Oversold
www.nasdaq.com - August 24 at 5:21 PM |
| Core Laboratories (CLB) Down 17.7% Since Earnings Report: Can It Rebound?
finance.yahoo.com - August 24 at 5:21 PM |
| Core Laboratories NV : CLB-US: Dividend Analysis : July 17th, 2017 (record date) : By the numbers : August 24, 2017
finance.yahoo.com - August 24 at 5:21 PM |
| Core Laboratories N.V. (CLB) Upgraded to "Outperform" by Credit Suisse Group
www.americanbankingnews.com - August 24 at 3:56 PM |
 | Core Laboratories Stock Upgraded: What You Need to Know
www.fool.com - August 24 at 2:47 PM |
| Behind Baker Hughes’s Correlation with Crude in Mid-August
finance.yahoo.com - August 22 at 5:49 PM |
| Correlation between Weatherford and Crude Oil on August 18
finance.yahoo.com - August 21 at 5:03 PM |
| How Core Laboratories N.V. Makes Most of Its Money
www.fool.com - August 21 at 11:23 AM |
| Flotek Industries’ Current Valuation versus Its Peers
finance.yahoo.com - August 18 at 5:18 PM |
| November 17th Options Now Available For Core Laboratories (CLB) - Nasdaq
www.nasdaq.com - August 17 at 11:37 PM |
| Core Laboratories N.V. (CLB) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - August 16 at 12:42 AM |
| ETFs with exposure to Core Laboratories NV : August 14, 2017
finance.yahoo.com - August 14 at 5:37 PM |
| Oilfield Tech & Innovation Day: Heavy Hitters, Cutting Edge Technologies coming to EnerCom Denver
finance.yahoo.com - August 9 at 5:27 PM |
| Head-To-Head Survey: Core Laboratories N.V. (NYSE:CLB) and Carbo Ceramics (CRR)
www.americanbankingnews.com - August 9 at 8:40 AM |
| Correlation between Weatherford and Crude Oil on August 4
finance.yahoo.com - August 8 at 4:57 PM |
| Morgan Stanley Lowers Core Laboratories N.V. (CLB) Price Target to $125.00
www.americanbankingnews.com - August 7 at 10:58 AM |
| Core Laboratories N.V. (NYSE:CLB) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - August 6 at 11:20 AM |
| NOW Inc's Results Continue Heading in the Right Direction
finance.yahoo.com - August 2 at 6:01 PM |
| Where the World Gets Its Power
finance.yahoo.com - July 31 at 5:11 PM |
| Core Laboratories NV :CLB-US: Earnings Analysis: Q2, 2017 By the Numbers : July 31, 2017
finance.yahoo.com - July 31 at 5:11 PM |
| Core Laboratories N.V. (NYSE:CLB) Short Interest Update
www.americanbankingnews.com - July 31 at 7:04 AM |
| Wall Street’s Forecasts for TechnipFMC after Its 2Q17 Earnings
finance.yahoo.com - July 28 at 6:58 PM |
| Core Laboratories N.V. (CLB) PT Lowered to $100.00
www.americanbankingnews.com - July 26 at 6:51 PM |
| Core Laboratories NV breached its 50 day moving average in a Bearish Manner : CLB-US : July 26, 2017
finance.yahoo.com - July 26 at 5:50 PM |
| Core Laboratories NV breached its 50 day moving average in a Bearish Manner : CLB-US : July 26, 2017
finance.yahoo.com - July 26 at 5:50 PM |
| Core Laboratories N.V.'s (CLB) "Neutral" Rating Reaffirmed at UBS AG
www.americanbankingnews.com - July 26 at 2:41 PM |
| What’s Schlumberger’s Correlation with Crude Oil after 2Q17?
finance.yahoo.com - July 26 at 3:16 AM |
 | Core Laboratories' (CLB) CEO David Demshur on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - July 25 at 10:14 PM |
| Edited Transcript of CLB earnings conference call or presentation 25-Jul-17 12:30pm GMT
finance.yahoo.com - July 25 at 10:14 PM |
| Core Laboratories (CLB) Q2 Earnings Top Estimates, Sales Lag - Nasdaq
www.nasdaq.com - July 25 at 5:14 PM |
| Core Laboratories N.V. (NYSE:CLB) Issues Earnings Results
www.americanbankingnews.com - July 25 at 9:08 AM |
| The Recovery in Core Laboratories N.V.'s Results Accelerated in the Second Quarter
www.fool.com - July 25 at 9:00 AM |
 | Core Lab Reports Second Quarter 2017 Results: - PR Newswire (press release)
www.prnewswire.com - July 24 at 9:56 PM |
| Core Laboratories beats 2Q profit forecasts
finance.yahoo.com - July 24 at 9:56 PM |
Core Laboratories N.V. (CLB) Chart for Monday, September, 25, 2017
